Context
After 10 years of being successfully listed on Euronext Brussels, Ablynx pursues a USD 230m NASDAQ listing off the back of successful phase III results in Capla, furthering its transformation into a leading European biopharma company.
Ablynx is a unique, versatile and validated Nanobodytechnology platform combining the key advantages of mAbs and small molecules; with the proven capability to generate multi-functional molecules, and the ability to utilize targeted routes of drug administration and modulate half-life.
It has a broad and diversified portfolio with more than 45 wholly-owned and partnered programmes (8 in clinical development).
It has developed Caplacizumab, (wholly-owned): Compelling Phase III data in the ~€800M1p.a. orphan a TTP market potentially supporting regulatory approval in the near-term in Europe and the U.S.A
Additionally, ALX-0171, (also wholly-owned): a potential breakthrough in the €1Bn+ RSV market, pioneering pulmonary delivery of biologics.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno - oncology, oncology and respiratory disease. Ablynx has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals.
Bryan, Garnier & Co acts as Co-manager for Ablynx Nasdaq IPO raising USD 230 million
Bryan, Garnier & Co was the sole European bank to be a member of the syndicate, underscoring our reach across Europe and the UK, particularly in the case of listed European issuers accessing the US capital market
Base deal upsized deal from USD 175 million to USD 200 million on back of strong demand and final raise of USD 230 million after greenshoe exercise.
Strong quality demand mainly from the US. Local demand mainly in ADSs.
Successful IPO with multiple oversubscription and successful conversion of roadshow meetings.
Robust aftermarket with +9% performance on ADR line and stable ORD line on 1st day of trading.
Bryan, Garnier & Co actively acting as Co-manager bringing more than USD 50 million in the book from Europe from Tier-1 specialists investors mainly from Benelux, Switzerland and the UK.
Largest US raise for company listed in Belgium.
#2 largest Biotech raise in 2017 YTD.
#3 largest ever US IPO for a European Biotech.
Share